Follow Iovance Biotherapeutics to never miss an important update.
After the Iovance November results, we raised our revenue and profit margin projections to match the company's faster pace of manufacturing. We updated our cash runway expectation to 2029 and dropped the risk that the business would need to sell more shares to fund operations. We added the opportunity for treating sarcoma to what we track and started monitoring how using biomarkers to select patients improves trial success rates.
The company brought in about 122 million dollars last quarter, an 80 percent jump from the same time last year. This growth was driven by Amtagvi, a personalized therapy that uses a patient's own immune cells to fight advanced skin cancer. The company also reached a 60 percent gross margin, which is the profit left after the direct costs of manufacturing these complex living drugs.
Beyond melanoma, the company shared data showing its therapy helped shrink tumors in about 25 percent of patients with a specific type of lung cancer. While the melanoma business is already growing, expanding into lung cancer and sarcoma would significantly increase the number of patients the company can treat. These results support a plan to ask regulators for approval in lung cancer by 2027.
See the full quarter, and how our tracked metrics did
Source: 8-K filing
The company reported that its cell therapy, lifileucel, continues to show promise for patients with advanced lung cancer who have already tried other treatments. In a specific group of patients identified by a biological marker, nearly 60 percent saw their tumors shrink. This is a high bar for this stage of the disease and suggests the therapy could work well beyond its current use in skin cancer.
These results are important because they give the company a clear path to file for FDA approval in 2027. Expanding into lung cancer would open up a much larger market than melanoma, which is currently the only area where the company's therapy is approved.
Source: GlobeNewsWire
In a study of patients with aggressive soft tissue cancers called sarcomas, the company's therapy led to tumor shrinkage in 50 percent of participants. These patients had already failed other treatments, making these results particularly notable for a group with very few options left. All of the patients who responded to the treatment are still seeing those benefits.
This data helps prove that the company's technology, which uses a patient's own immune cells to attack tumors, can work across different types of solid cancers. A larger trial is already underway to confirm these results, which could eventually lead to another approved use for the therapy.
Source: GlobeNewsWire
Management has built a reliable record of beating its own targets for five straight quarters, showing they have a firm handle on how fast their complex cancer therapy is scaling.
| Expectation | |
|---|---|
| EPS | $-0.09 |
| Revenue | $129M |
Follow Iovance Biotherapeutics to get the latest and most important updates.
Follow IOVA